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The Pi sampling method is derived from the incomplete
factorial approach to macromolecular crystallization screen
design. The resulting ‘Pi screens’ have a modular distribution
of a given set of up to 36 stock solutions. Maximally diverse
conditions can be produced by taking into account the
properties of the chemicals used in the formulation and
the concentrations of the corresponding solutions. The Pi
sampling method has been implemented in a web-based
application that generates screen formulations and recipes.
It is particularly adapted to screens consisting of 96 different
conditions. The ﬂexibility and efﬁciency of Pi sampling is
demonstrated by the crystallization of soluble proteins and
of an integral membrane-protein sample.
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1. Introduction
A crucial aspect of macromolecular crystallographic studies is
ﬁnding suitable conditions for the crystallization of a sample.
This can be difﬁcult because many factors alter the crystal-
lization behaviour of macromolecules, including the type and
the concentration of the chemicals employed to formulate the
conditions (McPherson, 1990). A condition includes at least
a precipitant and most conditions also include a buffer and an
additive. During the initial crystallization experiments, the
structure of the macromolecule is not known and hence the
most efﬁcient formulation cannot be predicted. As a conse-
quence, one should be cautious when making initial assump-
tions and limiting choices in subsequent optimizations (Rupp,
2003). Nonetheless, the number of initial crystallization con-
ditions cannot be unreasonably large since puriﬁed protein is
often difﬁcult and expensive to produce in large quantities.
There are essentially two approaches to restrict an initial
screen to a limited number of crystallization conditions.Firstly,
a sparse-matrix formulation can be used, which consists of
an empirically derived combination of components based on
known or published crystallization conditions (Jancarik &
Kim, 1991). Secondly, an incomplete factorial formulation can
be generated in which selected components are combined
to prepare new conditions in accordance with principles
of randomization and balance (Carter & Carter, 1979).
Numerous commercial screens based on these two main
approaches are available. Automated systems have been
implemented at the Medical Research Council (MRC)
Laboratory of Molecular Biology (LMB) to test these asroutine initial screens using the 96-well crystallization plate
format (Stock et al., 2005).However,for various reasons, many
laboratories opt for a minimal screen (Kimber et al., 2003)
and still perform at least some aspects of the work manually
(Bergfors, 2007).
Here, we present a development based on the incomplete
factorial formulation: the Pi sampling method. The name of
the method was inspired by the story of Archimedes, who used
the ‘method of exhaustion’ (i.e. an empirical approach) with a
96-sided polygon in order to reach the ﬁrst good numerical
approximation of  (Smith, 1958). Pi sampling uses modular
arithmetic to form combinations of three stock solutions
across a 96-condition grid. Maximally diverse conditions can
be produced by taking into account the properties of the
chemicals used in the formulation and the concentrations of
the corresponding stock solutions. We have implemented this
approach in a web-based application called Pi Sampler: user
input consists of the details of up to 36 stock solutions, from
which the application generates the formulations for a
96-condition screen. The Pi sampling method is intended to
help laboratories to test new crystallization-screen formula-
tions on a day-to-day basis based on the properties of the
macromolecules investigated, as has been performed pre-
viously with RNA (Doudna et al., 1993).
Firstly, we tested Pi sampling with ten commercially avail-
able soluble proteins. For this, the ‘Pi minimal screen’ was
employed including a wide variety of well known chemicals
frequently used for macromolecular crystallization.
We then investigated the impact of Pi sampling on the
crystallization of a G-protein-coupled receptor (GPCR) that
had been difﬁcult to crystallize: the adenosine A2A receptor
(construct A2AR-GL31). We formulated another Pi screen, the
‘Pi-PEG screen’, taking into consideration general observa-
tions made about crystallization of integral membrane-protein
samples. Previous crystallization experiments on another
GPCR (the 1-adrenergic receptor) had indicated that the use
of simple proprietary screens formulated with poly(ethylene
glycol) (PEG) and buffers gave a greater yield of crystals than
all commercially available screens, including those geared
towards membrane proteins (Warne et al., 2009), and the 2.7 A ˚
resolution structure was solved using conditions optimized
from a proprietary screen essentially based on PEGs (Warne
et al., 2008). This has been observed previously with other
membrane-protein targets (Lemieux et al., 2003). In addition,
mixtures of polyethylene glycols have been used successfully
to develop a minimal screen (Brzozowski & Walton, 2001) and
to study crystal structures of the Kir potassium channel
(Clarke et al., 2010). Such mixtures were incorporated into the
Pi-PEG screen.
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Figure 1
Pi sampling: combinations of stock solutions from three different sets (see
also http://pisampler.mrc-lmb.cam.ac.uk/).
Figure 2
Pi sampling: combinations of the stock solutions in a 96-condition plate layout (well A1 is at the top left corner). Each solution of set 1 (ID 1–12) is seen
in the eight conditions forming a column of the plate. The  values of set 1 increase from left to right in the screen layout. The positions of the solutions
A–L (set 2) shift across ﬁve columns and down one row ( values not represented). The positions of solutions M–X (set 3) shift across ten columns and
down one row. Gradients of concentration for sets 2 and 3 are represented on the left and right, respectively.2. Methods
2.1. Pi sampling
Pi sampling begins with up to 36 stock solutions, divided
into three sets of 12. The ﬁrst set of solutions is used in the
screen at constant concentration. The second and third sets
are added according to a gradient between speciﬁed minimum
and maximum concentrations. Typically, the ﬁrst set is com-
posed of buffers and the second and third sets are precipitants/
additives.
The combinations of three stock solutions (one from each
set) are generated according to Fig. 1, where 1–12 refer to the
IDs for solutions of the ﬁrst set, A–M to those of the second
set and N–X to those of the third set. The number in each cell
shows which solution of the ﬁrst set will be combined with the
corresponding solutions of the second and third sets. Blank
spaces show when no such combinations are generated.
Fig. 2 summarizes the distribution of the stock solutions in a
standard 96-condition plate layout (i.e. 12 columns and eight
rows).
Set 1: each solution (ID 1–12) is seen in the eight conditions
forming a column of the plate. A variable  should be asso-
ciated with the stock solutions. The variable  corresponds to
a property of the solution selected (e.g. pH, molecular weight
of the main chemical, absorption properties or others). 
values increase from left to right in the screen layout.
Set 2: each solution (ID A–L) is represented once in each
row. The ﬁnal concentrations decrease gradually from the top
to the bottom of the screen layout, forming a gradient. The
distribution of solutions A–L is based on the sequence of 
values established for set 1: the positions of the solutions shift
across ﬁve columns and down one row. Solutions A–L should
also be associated with a variable  and hence a sequence is
formed for the distribution of the third set of solutions.
Set 3: each solution (ID M–X) is also represented once in
each row. The ﬁnal concentrations increase gradually from the
top to the bottom of the screen, forming another gradient. The
solutions M–X are distributed with the same modulo arith-
metic operation as previously, but with respect to the  values
of solutions A–L. For example, solution M is mixed with
solution A in the ﬁrst row, solution F in the second row,
solution K in the third row and so on, as shown in Fig. 2. This
means that both the second and third sets are arranged
according to the same modulo arithmetic operation (5 modulo
12); however, when looking at the plate layout, the positions
of solutions M–X shift across ten columns and down one row.
2.2. Pi Sampler
Pi Sampler can be accessed via the internet at http://
pisampler.mrc-lmb.cam.ac.uk/. Users can enter the details
of up to 36 stock solutions, including stock concentrations,
desired screen concentration ranges and  values. The
application then generates a 96-condition screen formulation
following the Pi sampling method described above. Formula-
tions, recipes and total required volumes of stock solutions are
presented and may conveniently be downloaded in comma-
separated variable format (CSV), allowing the user to import
them into other software for automated screen making (Cox &
Weber, 1987), formulation analysis (Hedderich et al., 2011)
and data mining (Kantardjieff & Rupp, 2004). The parameters
used to generate the screen can also be saved and uploaded in
the same format. Further details and instructions can be found
on the website.
2.3. Pi minimal screen preparation and crystallization assays
with commercially available soluble proteins
The ﬁnal formulation of the Pi minimal screen can be found
in Table 1. There are 36 starting stock solutions overall. Each
solution composing the ﬁrst set (ID 1–12) is a mixture of an
acid with its corresponding base (e.g. HEPES pH 7.5: 1 M
HEPES solution mixed with 1 M HEPES sodium salt in order
to reach pH 7.5), except for buffer 11 (AMPD mixed with Tris
base). Note that this is also true for the precipitant phosphate
(phosphatesystem:sodium dihydrogenphosphate/dipotassium
hydrogen phosphate). Values of pH (4.0–9.5) were chosen as
the variable  for the ﬁrst set, whilst arbitrary values were
chosen for additives of various natures composing the second
set (IDA–L). Eventually, a few conditions were made without
additive/bufferbecauseofchemicalincompatibilities(Table1).
Highest purity grade chemicals (Molecular Biology grade
when available) were purchased from Sigma–Aldrich to
prepare 36 stock solutions. The solutions were mixed in 96
Falcon tubes. The screen was dispensed into ‘MRC original
plates’ (96-well, two-drop, Swissci; Stock et al., 2005).
Commercial proteins that had been crystallized before were
chosen to prepare test samples. Protein concentrations were
chosen randomly between 7 and 150 mg ml
 1 (Table 2).
Vapour-diffusion experiments were set up at 295 K, mixing
two different sample: condition ratios (1:3 and 3:1) to give a
ﬁnal volume of 400 nl. The plates were then stored at 291 K. A
condition was considered to be a hit when at least one of the
two corresponding drops contained crystals with well known
morphology after one week. Table 3 shows the ‘hits per con-
dition’ observed and the corresponding results expected for
the binomial distribution (see x4.2).
2.4. Pi-PEG screen preparation and crystallization assays
with a GPCR
The ﬁnal formulation of the Pi-PEG screen can be found in
Table 4. The formulation can also be generated using Pi
Sampler by loading the Pi-PEG example data. The pH values
(4.8–8.8) were chosen as the variable  for the buffers
composing set 1 (ID 1–12), whilst molecular weight was
chosen for set 2 (PEGs A–L, ﬁnal concentration range 0–
22.5%). The same 12 PEGs were used for set 3 (PEGs M–X,
ﬁnal concentration range 0–45%). General details of the
preparation are similar to x2.3, but there are 24 stock solutions
at the start (instead of 36). Vapour-diffusion experiments were
set up at 277 K, mixing sample and condition in a 1:1 ratio to
give a ﬁnal volume of 200 nl. The preparation of A2AR-GL31
will be published elsewhere (Lebon et al., submitted work).
Crystal X-ray screening was performed at the Diamond
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Table 1
Final formulation of the Pi minimal screen.
ADA, N-(2-acetamido)iminodiacetic acid; AMPD, 2-amino-2-methyl-1,3-propanediol; CAPSO, 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid; HEPES,
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid; MOPS, 3-(N-morpholino)propanesulfonic acid; PEG, poly(ethylene glycol); TAPS, N-[Tris(hydroxymethyl)-
methyl]-3-aminopropanesulfonic acid.
Set 1 Set 2 Set 3
Well ID Name Conc. Unit ID Name Conc. Unit ID Name Conc. Unit
A1 1 Formate pH 4.0 0.15 M A Potassium bromide 0.160 M M Phosphate 0.6 M
A2 2 Acetate pH 4.5 0.15 M B PEG 300 8.000 %(v/v) N PEG MME 550 24.00 %(v/v)
A3 3 Malate pH 5.0 0.15 M C Magnesium sulfate 0.160 M O Ammonium nitrate 2.0 M
A4 4 Citrate pH 5.5 0.15 M D Sodium ﬂuoride 0.032 M P PEG 20 000 10.0 %(w/v)
A5 5 MES pH 6.0 0.15 M E Potassium thiocyanate 0.080 M Q PEG 1000 30.0 %(w/v)
A6 6 Cacodylate pH 6.5 0.15 M F Sodium iodide 0.160 M R Sodium chloride 1.6 M
A7 7 MOPS pH 7.0 0.15 M G Propanediol 8.000 %(v/v) S PEG 4000 24.0 %(w/v)
A8 8 HEPES pH 7.5 0.15 M H T Lithium sulfate 0.8 M
A9 9 Tris pH 8.0 0.15 M I Ethylene glycol 8.000 %(v/v) U PEG MME 5000 20.0 %(w/v)
A10 10 TAPS pH 8.5 0.15 M J Sodium potassium tartrate 0.080 M V Glycerol 36.0 %(w/v)
A11 11 AMPD/Tris pH 9.0 0.15 M K MPD 8.000 %(v/v) W Ammonium sulfate 1.4 M
A12 12 CAPSO pH 9.5 0.15 M L 2-Butanol 8.000 %(v/v) X PEG 8000 20.0 %(w/v)
B1 1 Formate pH 4.0 0.15 M H Calcium chloride 0.070 M O Ammonium nitrate 2.3 M
B2 2 Acetate pH 4.5 0.15 M I Ethylene glycol 7.000 %(v/v) P PEG 20 000 12.0 %(w/v)
B3 3 Malate pH 5.0 0.15 M J Sodium potassium tartrate 0.070 M Q PEG 1000 35.0 %(w/v)
B4 4 Citrate pH 5.5 0.15 M K MPD 7.000 %(v/v) R Sodium chloride 1.8 M
B5 5 MES pH 6.0 0.15 M L 2-Butanol 7.000 %(v/v) S PEG 4000 28.0 %(w/v)
B6 6 Cacodylate pH 6.5 0.15 M A Potassium bromide 0.140 M T Lithium sulfate 0.9 M
B7 7 MOPS pH 7.0 0.15 M B PEG 300 7.000 %(v/v) U PEG MME 5000 23.0 %(w/v)
B8 8 HEPES pH 7.5 0.15 M C Magnesium sulfate 0.140 M V Glycerol 42.0 %(w/v)
B9 9 Tris pH 8.0 0.15 M D Sodium ﬂuoride 0.028 M W Ammonium sulfate 1.6 M
B10 10 TAPS pH 8.5 0.15 M E Potassium thiocyanate 0.070 M X PEG 8000 23.0 %(w/v)
B11 11 AMPD/Tris pH 9.0 0.15 M F Sodium iodide 0.140 M M Phosphate 0.7 M
B12 12 CAPSO pH 9.5 0.15 M G Propanediol 7.000 %(v/v) N PEG MME 550 28.00 %(v/v)
C1 1 Formate pH 4.0 0.15 M C Magnesium sulfate 0.120 M Q PEG 1000 39.0 %(w/v)
C2 2 Acetate pH 4.5 0.15 M D Sodium ﬂuoride 0.024 M R Sodium chloride 2.1 M
C3 3 Malate pH 5.0 0.15 M E Potassium thiocyanate 0.060 M S PEG 4000 31.0 %(w/v)
C4 4 Citrate pH 5.5 0.15 M F Sodium iodide 0.120 M T Lithium sulfate 1.0 M
C5 5 MES pH 6.0 0.15 M G Propanediol 6.000 %(v/v) U PEG MME 5000 26.0 %(w/v)
C6 6 Cacodylate pH 6.5 0.15 M H Calcium chloride 0.060 M V Glycerol 47.0 %(w/v)
C7 7 MOPS pH 7.0 0.15 M I Ethylene glycol 6.000 %(v/v) W Ammonium sulfate 1.8 M
C8 8 HEPES pH 7.5 0.15 M J Sodium potassium tartrate 0.060 M X PEG 8000 26.0 %(w/v)
C9 9 Tris pH 8.0 0.15 M K MPD 6.000 %(v/v) M Phosphate 0.8 M
C10 10 TAPS pH 8.5 0.15 M L 2-Butanol 6.000 %(v/v) N PEG MME 550 31.00 %(v/v)
C11 11 AMPD/Tris pH 9.0 0.15 M A Potassium bromide 0.120 M O Ammonium nitrate 2.6 M
C12 12 CAPSO pH 9.5 0.15 M B PEG 300 6.000 %(v/v) P PEG 20 000 13.0 %(w/v)
D1 1 Formate pH 4.0 0.15 M J S PEG 4000 35.0 %(w/v)
D2 2 Acetate pH 4.5 0.15 M K MPD 5.000 %(v/v) T Lithium sulfate 1.1 M
D3 3 Malate pH 5.0 0.15 M L 2-Butanol 5.000 %(v/v) U PEG MME 5000 38.00 %(v/v)
D4 4 Citrate pH 5.5 0.15 M A Potassium bromide 0.100 M V Glycerol 52.0 %(w/v)
D5 5 MES pH 6.0 0.15 M B PEG 300 5.000 %(v/v) W Ammonium sulfate 2.0 M
D6 6 Cacodylate pH 6.5 0.15 M C Magnesium sulfate 0.100 M X PEG 8000 29.0 %(w/v)
D7 7 MOPS pH 7.0 0.15 M D Sodium ﬂuoride 0.020 M M Phosphate 0.9 M
D8 8 HEPES pH 7.5 0.15 M E Potassium thiocyanate 0.050 M N PEG MME 550 34.00 %(v/v)
D9 9 Tris pH 8.0 0.15 M F Sodium iodide 0.100 M O Ammonium nitrate 2.9 M
D10 10 TAPS pH 8.5 0.15 M G Propanediol 5.000 %(v/v) P PEG 20 000 15.0 %(w/v)
D11 11 H Calcium chloride 0.050 M Q PEG 1000 43.0 %(w/v)
D12 12 CAPSO pH 9.5 0.15 M I Ethylene glycol 5.000 %(v/v) R Sodium chloride 2.3 M
E1 1 Formate pH 4.0 0.15 M E Potassium thiocyanate 0.040 M U PEG MME 5000 32.0 %(w/v)
E2 2 Acetate pH 4.5 0.15 M F Sodium iodide 0.080 M V Glycerol 57.0 %(w/v)
E3 3 Malate pH 5.0 0.15 M G Propanediol 4.000 %(v/v) W Ammonium sulfate 2.2 M
E4 4 Citrate pH 5.5 0.15 M H X PEG 8000 32.0 %(w/v)
E5 5 MES pH 6.0 0.15 M I Ethylene glycol 4.000 %(v/v) M Phosphate 0.9 M
E6 6 Cacodylate pH 6.5 0.15 M J Sodium potassium tartrate 0.040 M N PEG MME 550 38.0 %(v/v)
E7 7 MOPS pH 7.0 0.15 M K MPD 4.000 %(v/v) O Ammonium nitrate 3.1 M
E8 8 HEPES pH 7.5 0.15 M L 2-Butanol 4.000 %(v/v) P PEG 20 000 16.0 %(w/v)
E9 9 Tris pH 8.0 0.15 M A Potassium bromide 0.080 M Q PEG 1000 48.0 %(w/v)
E10 10 TAPS pH 8.5 0.15 M B PEG 300 4.000 %(v/v) R Sodium chloride 2.5 M
E11 11 AMPD/Tris pH 9.0 0.15 M C Magnesium sulfate 0.080 M S PEG 4000 38.0 %(w/v)
E12 12 CAPSO pH 9.5 0.15 M D T Lithium sulfate 1.3 M
F1 1 Formate pH 4.0 0.15 M L 2-Butanol 3.000 %(v/v) W Ammonium sulfate 2.4 M
F2 2 Acetate pH 4.5 0.15 M A Potassium bromide 0.060 M X PEG 8000 35.0 %(w/v)
F3 3 Malate pH 5.0 0.15 M B PEG 300 3.000 %(v/v) M Phosphate 1.0 M
F4 4 C Magnesium sulfate 0.06 M N PEG MME 550 42.00 %(v/v)
F5 5 MES pH 6.0 0.15 M D Sodium ﬂuoride 0.012 M O Ammonium nitrate 3.4 Msynchrotron light source (microfocus
beamline I24 equipped with a Pilatus
6M detector).
3. Results
There were 116 crystallization hits
overall for the experiments with the Pi
minimal screen (Table 2). Some condi-
tions produced hits for several samples
(Table 3).
The Pi-PEG screen yielded crystals
that diffracted to 3.0 A ˚ resolution for
A2AR-GL31 with bound agonist. Fig. 3
shows the crystals of A2AR-GL31
obtained in well E9 [50 mM Tris–HCl
pH 7.6, 9.6%(v/v) PEG 200, 22.9%(v/v)
PEG 300] and an example of the
corresponding diffraction pattern (no
cryoprotectant was required).
4. Discussion
4.1. Pi sampling
In order to understand the rationale
behind the modular arithmetic
research papers
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Table 2
Details of the samples used with the Pi minimal screen (Table 1) and number of crystallization hits.
TEN, buffer consisting of 20 mM 2-amino-2-(hydroxymethyl)-1,3-propanediol (Tris), 1 mM ethylene-
diaminetetraacetic acid (EDTA), 1 mM sodium azide and 200 mM sodium chloride.
Protein Concentration
(mg ml
 1)
MW
(kDa)
Source and code Buffer/preparation Hits
Lysozyme 10.0 14.4 Sigma L6876 Deionized water 56
Concanavalin A 7.0 26.5 Sigma L7647 TEN pH 8.5 16
Glucose isomerase 33.0 43.0 Hampton HR7-102 See product user guide 11
Xylanase 36.0 21.0 Hampton HR7-106 See product user guide 8
Ferritin 50–150 440.0 Fluka 96701 As supplied by the manufacturer 8
Catalase 12.6 62.5 Sigma C3155 Deionized water 6
Citrate synthase 10.0 49.0 Sigma C3260 TEN pH 8.5 5
Lipase B 25.0 35.0 Hampton HR7-099 Deionized water 4
Ribonuclease A 30.0 13.7 Sigma R5503 Deionized water 1
Thaumatin 30.0 22.0 Sigma T7638 Deionized water 1
Sum 116
Table 3
‘Hits per condition’ observed and corresponding results expected with the binomial distribution (Pi
minimal screen).
Hits/condition Observed Expected
0 21 26.5
1 45 36.4
2 20 22.5
3 or more 10 10.6
Sum 96 96
Table 3 (continued)
Set 1 Set 2 Set 3
Well ID Name Conc. Unit ID Name Conc. Unit ID Name Conc. Unit
F6 6 Cacodylate pH 6.5 0.15 M E Potassium thiocyanate 0.030 M P PEG 20 000 18.0 %(w/v)
F7 7 MOPS pH 7.0 0.15 M F Sodium iodide 0.060 M Q PEG 1000 52.0 %(w/v)
F8 8 HEPES pH 7.5 0.15 M G Propanediol 3.000 %(v/v) R Sodium chloride 2.7 M
F9 9 Tris pH 8.0 0.15 M H Calcium chloride 0.030 M S PEG 4000 42.0 %(w/v)
F10 10 TAPS pH 8.5 0.15 M I Ethylene glycol 3.000 %(v/v) T Lithium sulfate 1.4 M
F11 11 AMPD/Tris pH 9.0 0.15 M J Sodium potassium tartrate 0.030 M U PEG MME 5000 35.0 %(w/v)
F12 12 CAPSO pH 9.5 0.15 M K MPD 3.000 %(v/v) V Glycerol 62.0 %(w/v)
G1 1 Formate pH 4.0 0.15 M G Propanediol 2.000 %(v/v) M Phosphate 1.1 M
G2 2 Acetate pH 4.5 0.15 M H N PEG MME 550 45.00 %(v/v)
G3 3 Malate pH 5.0 0.15 M I Ethylene glycol 2.000 %(v/v) O Ammonium nitrate 3.7 M
G4 4 Citrate pH 5.5 0.15 M J Sodium potassium tartrate 0.020 M P PEG 20 000 19.0 %(w/v)
G5 5 MES pH 6.0 0.15 M K MPD 2.000 %(v/v) Q PEG 1000 56.0 %(w/v)
G6 6 Cacodylate pH 6.5 0.15 M L 2-Butanol 2.000 %(v/v) R Sodium chloride 3.0 M
G7 7 MOPS pH 7.0 0.15 M A Potassium bromide 0.040 M S PEG 4000 45.0 %(w/v)
G8 8 HEPES pH 7.5 0.15 M B PEG 300 2.000 %(v/v) T Lithium sulfate 1.5 M
G9 9 Tris pH 8.0 0.15 M C Magnesium sulfate 0.040 M U PEG MME 5000 38.0 %(w/v)
G10 10 TAPS pH 8.5 0.15 M D Sodium ﬂuoride 0.008 M V Glycerol 67.0 %(w/v)
G11 11 AMPD/Tris pH 9.0 0.15 M E Potassium thiocyanate 0.020 M W Ammonium sulfate 2.6 M
G12 12 CAPSO pH 9.5 0.15 M F Sodium iodide 0.040 M X PEG 8000 38.0 %(w/v)
H1 1 Formate pH 4.0 0.15 M B PEG 300 1.000 %(v/v) O Ammonium nitrate 4.0 M
H2 2 Acetate pH 4.5 0.15 M C Magnesium sulfate 0.020 M P PEG 20 000 20.0 %(w/v)
H3 3 Malate pH 5.0 0.15 M D Sodium ﬂuoride 0.004 M Q PEG 1000 60.0 %(w/v)
H4 4 Citrate pH 5.5 0.15 M E Potassium thiocyanate 0.010 M R Sodium chloride 3.2 M
H5 5 MES pH 6.0 0.15 M F Sodium iodide 0.020 M S PEG 4000 48.0 %(w/v)
H6 6 Cacodylate pH 6.5 0.15 M G Propanediol 1.000 %(v/v) T Lithium sulfate 1.6 M
H7 7 MOPS pH 7.0 0.15 M H Calcium chloride 0.010 M U PEG MME 5000 40.0 %(w/v)
H8 8 HEPES pH 7.5 0.15 M I Ethylene glycol 1.000 %(v/v) V Glycerol 72.0 %(w/v)
H9 9 Tris pH 8.0 0.15 M J Sodium potassium tartrate 0.010 M W Ammonium sulfate 2.8 M
H10 10 TAPS pH 8.5 0.15 M K MPD 1.000 %(v/v) X PEG 8000 40.0 %(w/v)
H11 11 AMPD/Tris pH 9.0 0.15 M L 2-Butanol 1.000 %(v/v) M Phosphate 1.2 M
H12 12 CAPSO pH 9.5 0.15 M A Potassium bromide 0.020 M N PEG MME 550 48.00 %(v/v)
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Table 4
Final formulation of the Pi-PEG screen.
Set 1 Set 2 Set 3
Well ID Name Conc. Unit ID Name Conc. Unit ID Name Conc. Unit
A1 1 Acetate pH 4.8 0.05 M A PEG 200 22.5 %(v/v)M
A2 2 Acetate pH 5.2 0.05 M B PEG 300 20.0 %(v/v)N
A3 3 MES pH 5.6 0.05 M C PEG MME 350 20.0 %(v/v)O
A4 4 MES pH 6.0 0.05 M D PEG 400 20.0 %(v/v)P
A5 5 ADA pH 6.4 0.05 M E PEG MME 550 20.0 %(v/v)Q
A6 6 ADA pH 6.8 0.05 M F PEG 600 20.0 %(v/v)R
A7 7 HEPES pH 7.1 0.05 M G PEG 1000 17.5 %(w/v)S
A8 8 HEPES pH 7.3 0.05 M H PEG 1500 17.5 %(w/v)T
A9 9 Tris pH 7.6 0.05 M I PEG 2000 15.0 %(w/v)U
A10 10 Tris pH 8.0 0.05 M J PEG MME 2000 15.0 %(w/v)V
A11 11 Bicine pH 8.4 0.05 M K PEG 3000 15.0 %(w/v)W
A12 12 Bicine pH 8.8 0.05 M L PEG 4000 15.0 %(w/v)X
B1 1 Acetate pH 4.8 0.05 M H PEG 1500 15.0 %(w/v) O PEG 4000 3.6 %(w/v)
B2 2 Acetate pH 5.2 0.05 M I PEG 2000 12.9 %(w/v) P PEG 200 6.4 %(v/v)
B3 3 MES pH 5.6 0.05 M J PEG MME 2000 12.9 %(w/v) Q PEG 300 5.7 %(v/v)
B4 4 MES pH 6.0 0.05 M K PEG 3000 12.9 %(w/v) R PEG MME 350 5.7 %(v/v)
B5 5 ADA pH 6.4 0.05 M L PEG 4000 12.9 %(w/v) S PEG 400 5.7 %(v/v)
B6 6 ADA pH 6.8 0.05 M A PEG 200 19.3 %(v/v) T PEG MME 550 5.7 %(v/v)
B7 7 HEPES pH 7.1 0.05 M B PEG 300 17.1 %(v/v) U PEG 600 5.7 %(v/v)
B8 8 HEPES pH 7.3 0.05 M C PEG MME 350 17.1 %(v/v) V PEG 1000 5.0 %(w/v)
B9 9 Tris pH 7.6 0.05 M D PEG 400 17.1 %(v/v) W PEG 1500 5.0 %(w/v)
B10 10 Tris pH 8.0 0.05 M E PEG MME 550 17.1 %(v/v) X PEG 2000 4.3 %(w/v)
B11 11 Bicine pH 8.4 0.05 M F PEG 600 17.1 %(v/v) M PEG MME 2000 4.3 %(w/v)
B12 12 Bicine pH 8.8 0.05 M G PEG 1000 15.0 %(w/v) N PEG 3000 4.3 %(w/v)
C1 1 Acetate pH 4.8 0.05 M C PEG MME 350 14.3 %(v/v) Q PEG 300 11.4 %(v/v)
C2 2 Acetate pH 5.2 0.05 M D PEG 400 14.3 %(v/v) R PEG MME 350 11.4 %(v/v)
C3 3 MES pH 5.6 0.05 M E PEG MME 550 14.3 %(v/v) S PEG 400 11.4 %(v/v)
C4 4 MES pH 6.0 0.05 M F PEG 600 14.3 %(v/v) T PEG MME 550 11.4 %(v/v)
C5 5 ADA pH 6.4 0.05 M G PEG 1000 12.5 %(w/v) U PEG 600 11.4 %(v/v)
C6 6 ADA pH 6.8 0.05 M H PEG 1500 12.5 %(w/v) V PEG 1000 10.0 %(w/v)
C7 7 HEPES pH 7.1 0.05 M I PEG 2000 10.7 %(w/v) W PEG 1500 10.0 %(w/v)
C8 8 HEPES pH 7.3 0.05 M J PEG MME 2000 10.7 %(w/v) X PEG 2000 8.6 %(w/v)
C9 9 Tris pH 7.6 0.05 M K PEG 3000 10.7 %(w/v) M PEG MME 2000 8.6 %(w/v)
C10 10 Tris pH 8.0 0.05 M L PEG 4000 10.7 %(w/v) N PEG 3000 8.6 %(w/v)
C11 11 Bicine pH 8.4 0.05 M A PEG 200 16.1 %(v/v) O PEG 4000 7.1 %(w/v)
C12 12 Bicine pH 8.8 0.05 M B PEG 300 14.3 %(v/v) P PEG 200 12.9 %(v/v)
D1 1 Acetate pH 4.8 0.05 M J PEG MME 2000 8.6 %(w/v) S PEG 400 17.1 %(w/v)
D2 2 Acetate pH 5.2 0.05 M K PEG 3000 8.6 %(w/v) T PEG MME 550 17.1 %(v/v)
D3 3 MES pH 5.6 0.05 M L PEG 4000 8.6 %(w/v) U PEG 600 17.1 %(v/v)
D4 4 MES pH 6.0 0.05 M A PEG 200 12.9 %(v/v) V PEG 1000 15.0 %(w/v)
D5 5 ADA pH 6.4 0.05 M B PEG 300 11.4 %(v/v) W PEG 1500 15.0 %(w/v)
D6 6 ADA pH 6.8 0.05 M C PEG MME 350 11.4 %(v/v) X PEG 2000 12.9 %(w/v)
D7 7 HEPES pH 7.1 0.05 M D PEG 400 11.4 %(v/v) M PEG MME 2000 12.9 %(w/v)
D8 8 HEPES pH 7.3 0.05 M E PEG MME 550 11.4 %(v/v) N PEG 3000 12.9 %(w/v)
D9 9 Tris pH 7.6 0.05 M F PEG 600 11.4 %(v/v) O PEG 4000 10.7 %(w/v)
D10 10 Tris pH 8.0 0.05 M G PEG 1000 10.0 %(w/v) P PEG 200 19.3 %(v/v)
D11 11 Bicine pH 8.4 0.05 M H PEG 1500 10.0 %(w/v) Q PEG 300 17.1 %(v/v)
D12 12 Bicine pH 8.8 0.05 M I PEG 2000 8.6 %(w/v) R PEG MME 350 17.1 %(v/v)
E1 1 Acetate pH 4.8 0.05 M E PEG MME 550 8.6 %(v/v) U PEG 600 22.9 %(v/v)
E2 2 Acetate pH 5.2 0.05 M F PEG 600 8.6 %(v/v) V PEG 1000 20.0 %(w/v)
E3 3 MES pH 5.6 0.05 M G PEG 1000 7.5 %(w/v) W PEG 1500 20.0 %(w/v)
E4 4 MES pH 6.0 0.05 M H PEG 1500 7.5 %(w/v) X PEG 2000 17.1 %(w/v)
E5 5 ADA pH 6.4 0.05 M I PEG 2000 6.4 %(w/v) M PEG MME 2000 17.1 %(w/v)
E6 6 ADA pH 6.8 0.05 M J PEG MME 2000 6.4 %(w/v) N PEG 3000 17.1 %(w/v)
E7 7 HEPES pH 7.1 0.05 M K PEG 3000 6.4 %(w/v) O PEG 4000 14.3 %(w/v)
E8 8 HEPES pH 7.3 0.05 M L PEG 4000 6.4 %(w/v) P PEG 200 25.7 %(v/v)
E9 9 Tris pH 7.6 0.05 M A PEG 200 9.6 %(v/v) Q PEG 300 22.9 %(v/v)
E10 10 Tris pH 8.0 0.05 M B PEG 300 8.6 %(v/v) R PEG MME 350 22.9 %(v/v)
E11 11 Bicine pH 8.4 0.05 M C PEG MME 350 8.6 %(v/v) S PEG 400 22.9 %(v/v)
E12 12 Bicine pH 8.8 0.05 M D PEG 400 8.6 %(v/v) T PEG MME 550 22.9 %(v/v)
F1 1 Acetate pH 4.8 0.05 M L PEG 4000 4.3 %(w/v) W PEG 1500 25.0 %(w/v)
F2 2 Acetate pH 5.2 0.05 M A PEG 200 6.4 %(v/v) X PEG 2000 21.4 %(w/v)
F3 3 MES pH 5.6 0.05 M B PEG 300 5.7 %(v/v) M PEG MME 2000 21.4 %(w/v)
F4 4 MES pH 6.0 0.05 M C PEG MME 350 5.7 %(v/v) N PEG 3000 21.4 %(w/v)
F5 5 ADA pH 6.4 0.05 M D PEG 400 5.7 %(v/v) O PEG 4000 17.9 %(w/v)
F6 6 ADA pH 6.8 0.05 M E PEG MME 550 5.7 %(v/v) P PEG 200 32.1 %(v/v)
F7 7 HEPES pH 7.1 0.05 M F PEG 600 5.7 %(v/v) Q PEG 300 28.6 %(v/v)
F8 8 HEPES pH 7.3 0.05 M G PEG 1000 5.0 %(w/v) R PEG MME 350 28.6 %(v/v)
F9 9 Tris pH 7.6 0.05 M H PEG 1500 5.0 %(w/v) S PEG 400 28.6 %(v/v)employed for the Pi sampling, it may help to imagine, on a 12 h
clock, a series of events occurring every 5 h. The ﬁrst event is
at noon, the second at 5 pm, then 10 pm, then 3 am etc.
Eventually, there is a succession of 12 events occurring at
different hours, with as much time as possible in between each
event. If we now look at combinations of three components,
there are originally 12
3 or 1728 possibilities. Pi Sampler
generates 96 of these combinations that correspond to
conditions that are distant in properties. The variety between
conditions is then accentuated using a
number of different concentrations of
solutions (Fig. 2). If the ﬁrst and second
sets of solutions are ordered according to
physico-chemical properties, the generated
screen will be an incomplete factorial
sampling of interactions between chemi-
cals with these properties. If the chemicals
selected have completely different natures,
they can be arranged randomly (see x2.3).
The ordering of the third set of solutions
can be used to avoid obvious chemical
incompatibilities (e.g. mixing phosphate
and magnesium salts). It is also possible to
design simplerscreens with only two sets of
stock solutions.
4.2. The Pi minimal screen
In order to check the homogeneity of
the hits across the screen with the ten
samples, we compared the results obtained with what would be
expected if each condition had the same probability of hits
overall (Table 3). This can be approximated by a binomial
distribution. The probability of success for the binomial
distribution is the observed probability for ten attempts: 116/
(10   96) = 0.12083. The 
2 statistic for the data is 3.48. This
can be compared with the quantiles of a 
2 distribution with
two degrees of freedom, which gives a p value of 0.18
(calculations not shown). This 
2 test indicates that no
research papers
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Table 4 (continued)
Set 1 Set 2 Set 3
Well ID Name Conc. Unit ID Name Conc. Unit ID Name Conc. Unit
F10 10 Tris pH 8.0 0.05 M I PEG 2000 4.3 %(w/v) T PEG MME 550 28.6 %(v/v)
F11 11 Bicine pH 8.4 0.05 M J PEG MME 2000 4.3 %(w/v) U PEG 600 28.6 %(v/v)
F12 12 Bicine pH 8.8 0.05 M K PEG 3000 4.3 %(w/v) V PEG 1000 25.0 %(w/v)
G1 1 Acetate pH 4.8 0.05 M G PEG 1000 2.5 %(w/v) M PEG MME 2000 25.7 %(w/v)
G2 2 Acetate pH 5.2 0.05 M H PEG 1500 2.5 %(w/v) N PEG 3000 25.7 %(w/v)
G3 3 MES pH 5.6 0.05 M I PEG 2000 2.1 %(w/v) O PEG 4000 21.4 %(w/v)
G4 4 MES pH 6.0 0.05 M J PEG MME 2000 2.1 %(w/v) P PEG 200 38.6 %(v/v)
G5 5 ADA pH 6.4 0.05 M K PEG 3000 2.1 %(w/v) Q PEG 300 34.3 %(v/v)
G6 6 ADA pH 6.8 0.05 M L PEG 4000 2.1 %(w/v) R PEG MME 350 34.3 %(v/v)
G7 7 HEPES pH 7.1 0.05 M A PEG 200 3.2 %(v/v) S PEG 400 34.3 %(v/v)
G8 8 HEPES pH 7.3 0.05 M B PEG 300 2.9 %(v/v) T PEG MME 550 34.3 %(v/v)
G9 9 Tris pH 7.6 0.05 M C PEG MME 350 2.9 %(v/v) U PEG 600 34.3 %(v/v)
G10 10 Tris pH 8.0 0.05 M D PEG 400 2.9 %(v/v) V PEG 1000 30.0 %(w/v)
G11 11 Bicine pH 8.4 0.05 M E PEG MME 550 2.9 %(v/v) W PEG 1500 30.0 %(w/v)
G12 12 Bicine pH 8.8 0.05 M F PEG 600 2.9 %(v/v) X PEG 2000 25.7 %(w/v)
H1 1 Acetate pH 4.8 0.05 M B O PEG 4000 25.0 %(w/v)
H2 2 Acetate pH 5.2 0.05 M C P PEG 200 45.0 %(v/v)
H3 3 MES pH 5.6 0.05 M D Q PEG 300 40.0 %(v/v)
H4 4 MES pH 6.0 0.05 M E R PEG MME 350 40.0 %(v/v)
H5 5 ADA pH 6.4 0.05 M F S PEG 400 40.0 %(v/v)
H6 6 ADA pH 6.8 0.05 M G T PEG MME 550 40.0 %(v/v)
H7 7 HEPES pH 7.1 0.05 M H U PEG 600 40.0 %(v/v)
H8 8 HEPES pH 7.3 0.05 M I V PEG 1000 35.0 %(w/v)
H9 9 Tris pH 7.6 0.05 M J W PEG 1500 35.0 %(w/v)
H10 10 Tris pH 8.0 0.05 M K X PEG 2000 30.0 %(w/v)
H11 11 Bicine pH 8.4 0.05 M L M PEG MME 2000 30.0 %(w/v)
H12 12 Bicine pH 8.8 0.05 M A N PEG 3000 30.0 %(w/v)
Figure 3
Crystals of A2AR-GL31 obtained with the Pi-PEG screen (Table 4) and an example of a
corresponding diffraction pattern.conditions are obvious outliers with regard to success or
failure. There are, however, a multitude of possible biases
implied when proceeding with crystallization experiments
(which would be even more accentuated with the use of novel
samples); hence, any statistical analysis should be taken
with precaution. Nonetheless, it is interesting to see that the
analysis of the distribution is in accordance with the original
approach based on balanced randomization (Carter & Carter,
1979; Rupp, 2003).
In addition, the conditions of the Pi minimal screen show
no identities to the extensive list of conditions (7230) from
commercial screens stored in the ‘PICKScreens’ database
(Hedderich et al., 2011).
4.3. The Pi-PEG screen
The extent of effects on crystallization for precipitants such
as PEGs is correlated with their concentrations (McPherson,
1976) and molecular weights (Forsythe et al., 2002). The Pi-
PEG screen covers a wide range of parameters (kinetics of
equilibrium, protein stabilization etc.). In addition, the con-
centrations of the two different PEGs in a condition can be
adjusted for condition optimization (Stock et al., 2005) and for
crystal cryoprotection (Berejnovet al., 2006). Furthermore, the
PICKScreens database shows that the Pi-PEG screen is
unique (as for the Pi minimal screen; see x4.2).
Samples of A2AR-GL31 puriﬁed in a number of different
detergents rarely crystallized in commercially available
screens used at the LMB (Stock et al., 2005) and when they did
the crystal quality was not sufﬁcient for structure determina-
tion. The ﬁrst quality crystals were recently obtained using the
Pi-PEG screen.
5. Conclusions
We have demonstrated that the Pi sampling is a methodical
and ﬂexible approach to initial screening for macromolecular
crystallization. Two unique screens produced de novo have
resulted from this strategy. The Pi minimal screen potentially
has an ideal formulation for crystallization of novel soluble
protein samples. The Pi-PEG screen is a tailor-made screen for
GPCRs and potentially other membrane proteins generated
by biasing the formulation towards components known to be
essential.
Further screens can be formulated with the Pi Sampler on a
day-to-day basis in order to test chemicals and techniques,
with the aim of increasing the yield of quality crystals. Also,
new crystallization techniques are constantly emerging for
macromolecular targets such as membrane proteins and hence
formulations with special considerations are required: one
may want to formulate screens compatible with the lipidic
cubic phase (LCP) concept (Landau & Rosenbusch, 1996) or
make extensive use of detergents (Koszelak-Rosenblum et al.,
2009).
In order for laboratories to be able to handle many Pi
screen formulations and the ﬂow of resulting data, we are
working on the integration of Pi Sampler into the ‘xtalPiMS’
Laboratory Information Management System (LIMS; Morris
et al., 2011; see http://www.pims-lims.org).
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